Furthermore, SRSF3 knockdown inhibits the exon 2 inclusion of CD19, thereby attenuating the effect of CAR-T therapy against this epitope and leading to high recurrence rates in B-ALL [31]. This evidence concerns the gene SRSF3 and precursor B-cell acute lymphoblastic leukemia.